Clinical Trials Logo
  1. Home
  2. Myeloproliferative Neoplasms
  3. NCT06291987

Ivosidenib and Ruxolitinib in Patients With Advanced Myeloproliferative Neoplasms (MPNs) That Have an IDH1 Gene Mutation — MPN  

Myeloproliferative Neoplasms Clinical Trial

Official title:
A Phase 1b Trial of Ivosidenib Combined With Ruxolitinib in IDH1-Mutated Advanced-Phase MPNs

Clinical Trial Summary

The purpose of this research is to gather information on the safety and effectiveness determining maximum tolerated dose (MTD) of ruxolitinib in combination with ivosidenib in IDH1-mutated advanced-phase Ph-negative MPNs while evaluate the efficacy of ruxolitinib in combination with ivosidenib in IDH1-mutated advanced-phase Ph-negative MPNs.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT06291987
Study type Interventional
Source University of Chicago
Contact Clinical Trials Intake
Phone 1-855-702-8222
Email cancerclinicaltrials@bsd.uchicago.edu
Status Not yet recruiting
Phase Phase 1
Start date May 20, 2024
Completion date May 2026
View Details
See also
  Status Clinical Trial Phase
Terminated NCT04866056 - Jaktinib and Azacitidine In Treating Patients With MDS With MF or MDS/MPN With MF. Phase 1/Phase 2
Recruiting NCT05936359 - A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms Phase 1
Completed NCT02084563 - Study of Molecular and Genetic Abnormalities in Patients With Myeloid Neoplasms Phase 2
Recruiting NCT04339400 - A Study of TQ05105 Tablets in Subjects With Myeloproliferative Neoplasms Phase 1
Completed NCT02125318 - A Study of Anagrelide Controlled Release (GALE-401) in Patients With High Platelet Counts Due to Bone Marrow Disorders Phase 2
Recruiting NCT03314974 - Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders Phase 2
Completed NCT03075826 - A Phase II Study of SGI-110 in Philadelphia-Negative Myeloproliferative Neoplasms Phase 2
Recruiting NCT02823210 - Clinical and Therapeutic Impact of Molecular Markers in Myeloproliferative Disorders
Not yet recruiting NCT06313593 - A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative Neoplasms Phase 1
Active, not recruiting NCT05444530 - A Study of VAC85135, a Neoantigen Vaccine Regimen, Concurrently Administered With Ipilimumab for the Treatment of Myeloproliferative Neoplasms Phase 1
Active, not recruiting NCT03912064 - A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT Phase 1
Terminated NCT02393248 - Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101) Phase 1/Phase 2
Completed NCT02076191 - Study of Combination Ruxolitinib and Decitabine Treatment for Accelerated Phase MPN or Post-MPN AML Phase 1/Phase 2
Active, not recruiting NCT04761770 - Study of a Geriatric Assessment to Plan a Treatment Approach for Older People With Various Blood Disorders Phase 2
Recruiting NCT06034002 - A Study to Evaluate INCA033989 Administered in Participants With Myeloproliferative Neoplasms Phase 1
Completed NCT00949364 - Pomalidomide in Patients With Myeloproliferative Neoplasms in Fibrotic Stage Phase 2
Completed NCT00053196 - Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Cancer Phase 2
Terminated NCT01668173 - HSP90 Inhibitor, AUY922, in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), and Refractory PV/ET Phase 2
Active, not recruiting NCT03618485 - Registry of Patients With MPNs in Taiwan